Coronavirus (COVID-19): new dedicated Yellow Card reporting site for medicines and medical devices

Reporting to the new site will enable the MHRA to rapidly identify new and emerging side effects and medical device incidents in COVID-19 treatment, inclluding side effects for medicines taken by patients to manage long-term …

Valproate Pregnancy Prevention Programme: temporary advice for management during coronavirus (COVID-19)

Guidance has been published to support initiation of valproate in female patients and for annual review and pregnancy testing during the coronavirus pandemic.

Immunomodulatory drugs and pregnancy prevention: temporary advice for management during coronavirus (COVID-19)

Guidance has been published about thalidomide, lenalidomide, and pomalidomide and the use of remote consultations and home pregnancy testing for patients taking them during COVID-19.

Letters and drug alerts sent to healthcare professionals in April 2020

A summary of letters and drug alerts recently sent to healthcare professionals.

Posted on the UK MHRA website on 21 May 2020